Table 1.
Baseline characteristics and comparison of reactogenicity
| All subjects | NH | Control | NH vs. Control | Reactions | No reaction | Reactions vs. No Reaction | |
|---|---|---|---|---|---|---|---|
| Number of Subjects | 193 | 85 | 108 | 125 | 68 | ||
| Age: median (IQR) | 61(48,74) | 74(68,83) | 48(39,56) | < 0.001 | 53(43,65) | 72(66,81) | < 0.001 |
| Age: range | 26–99 | 48–99 | 26–78 | 26–92 | 35–99 | ||
| Male | 102(53%) | 51(60%) | 51(47%) | 0.105 | 62(50%) | 40(59%) | 0.282 |
| Female | 91(47%) | 34(40%) | 57(53%) | 63(50%) | 28(41%) | ||
| Race: white | 163(84%) | 74(87%) | 89(82%) | 0.078 | 104(83%) | 59(87%) | 0.582 |
| Race: black | 20(10%) | 10(12%) | 10(9%) | 13(10%) | 7(10%) | ||
| Race: other | 10(5%) | 1(1%) | 9(8%) | 8(6%) | 2(3%) | ||
| Prior SARS-CoV-2 | 67(35%) | 34(40%) | 33(31%) | 0.224 | 41(33%) | 26(38%) | 0.649 |
| SARS-CoV-2-Naïve | 126(65%) | 51(60%) | 75(69%) | 84(67%) | 42(62%) | ||
| Control | 108(56%) | – | 108(100%) | 98(78%) | 10(15%) | < 0.001 | |
| NH | 85(44%) | 85(100%) | – | 27(22%) | 58(85%) | ||
| Any reaction | 125(65%) | 27(32%) | 98(91%) | < 0.001 | 125(100%) | – | |
| No reaction | 68(35%) | 58(68%) | 10(9%) | – | 68(100%) | ||
| Max severity: 1 | 70(36%) | 21(25%) | 49(45%) | 70(56%) | – | ||
| Max severity: 2 | 40(21%) | 6(7%) | 34(31%) | 40(32%) | – | ||
| Max severity: 3 | 15(8%) | 0(0%) | 15(14%) | 15(12%) | – | ||
| Any systemic | 87(46%) | 15(18%) | 72(67%) | < 0.001 | 87(70%) | – | |
| Any local | 117(61%) | 24(28%) | 93(86%) | < 0.001 | 117(94%) | – |
NH nursing home, IQR interquartile range